<DOC>
	<DOCNO>NCT01728792</DOCNO>
	<brief_summary>This study assess safety immunogenicity Takeda 's Tetravalent Dengue Vaccine Candidate ( TDV ) previously refer DENVax various dose schedule via subcutaneous ( SC ) intramuscular ( IM ) administration needle/syringe needle-free injector ( PharmaJet Stratis™ ) .</brief_summary>
	<brief_title>Impact SC v IM Administration DENVax ( TDV ) Safety Immunogenicity</brief_title>
	<detailed_description>The vaccine test study TDV . TDV test assess safety immunogenicity various dose schedule , route administration , delivery method healthy flavivirus-seronegative adult live dengue non-endemic country . The study enrol 80 participant . Participants randomly assign one five treatment group : - Group 1 : TDV SC injection Day 0 arm use needle/syringe - Group 2 : TDV IM injection Day 0 arm use needle/syringe - Group3 : TDV IM injection Days 0 90 use needle/syringe - Group 4 : TDV SC Day 0 arm use PharmaJet Stratis™ device - Group 5 : TDV IM Day 0 arm use PharmaJet Stratis™ device This single-center trial conduct United States . The overall time participate study 5 month . Participants make multiple visit clinic include final visit Day 120 safety follow-up assessment . This work support US Army Medical Research Materiel Command Contract No . W81XWH-12-C-0278 . The view , opinion and/or finding contain report author ( ) construe official Department Army position , policy decision unless designate documentation .</detailed_description>
	<mesh_term>Dengue</mesh_term>
	<criteria>1 . Men woman least 18 year ≤ 45 year age time screen . 2 . In good health determine medical history physical examination ( include blood pressure heart rate ) . 3 . Weight : Body Mass Index ( BMI ) ≤ 35 . 4 . Blood test negative antibody human immunodeficiency virus1 ( HIV1 ) , Hepatitis C , Hepatitis B surface antigen . 5 . Females surgically sterile postmenopausal must negative urine pregnancy test immediately prior vaccination willing use oral , implantable , transdermal injectable contraceptive another reliable mean contraception approve Investigator ( intrauterine device , female condom , diaphragm spermicidal foam , cervical cap , use condom sexual partner sterile sexual partner , abstinence ) screen blood sample Day 120 . 6 . Willing able give write informed consent participate . 7 . Willing able communicate Investigator understand requirement study . 8 . Access fix mobile telephone . Exclusion Criteria 1 . Any condition would limit participant 's ability complete study opinion Investigator . 2 . Any Grade 2 abnormality screen laboratory test . 3 . Febrile illness ( temperature ≥ 38°C 100.4°F ) moderate severe acute illness infection within three day vaccination . 4 . History significant dermatologic disease last 6 month , particularly maculopapular petechial rash . However , participant selflimited Candida infection cure , participant enrol evidence infection least 3 week prior date dosing . If participant acne limit face , topical medication allow except 2 week prior 4 week dose . Oral medication acne exclude 1 month prior start dose . 5 . History dengue fever , Japanese encephalitis , West Nile , Yellow Fever disease . 6 . Seropositivity dengue West Nile ( WN ) virus . 7 . History travel dengue endemic area include Caribbean , Mexico , Central America , South America Southeast Asia month prior screening , plan travel dengue endemic area study period . 8 . Extensive scar tattoo ( &gt; 50 % ) arm , shoulder , neck , face head could identify participant photo hinder evaluation injection site reaction . In addition , tattoo arm permit study one month final injection . 9 . History recur headache migraine ( frequent per week ) prescription medication treatment recur headache migraine . 10 . Hypersensitivity vaccine . 11 . Receipt plan receipt vaccine 4 week precede follow Day 0 90 injection . 12 . Previous vaccination ( clinical trial approve product ) yellow fever ( YF ) Japanese Encephalitis ( JE ) . 13 . Known suspected congenital acquire immunodeficiency immunosuppressive therapy , anticancer chemotherapy radiation therapy , within precede 6 month . 14 . Use systemic corticosteroid therapy within previous 6 month ( dose least 0.5 mg/kg/day prednisone equivalent ) . Topical prednisone permit currently use use within last month . Inhaled prednisone permit . 15 . Use nonsteroidal antiinflammatory drug ( NSAIDs ) , acetaminophen antihistamine 3 day immediately prior vaccination . 16 . History diabetes mellitus . 17 . History thymic pathology , thymectomy , myasthenia immunodeficiency . 18 . Positive urine screen cocaine , amphetamine , opiate , cannabinoids 19 . Known history alcohol abuse . 20 . Receipt investigational product participation clinical trial product device within 30 day first vaccination ( Day 0 ) plan participation clinical trial enrol trial ( though Day 120 ) . 21 . Receipt blood product immunoglobulins 8 week first vaccination ( Day 0 ) plan use period study ( Day 120 ) . 22 . Planned donation blood period study ( Day 120 ) . 23 . Females pregnant lactating .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Prophylactic vaccination</keyword>
</DOC>